Abstract
Transarterial chemoembolization (TACE) is the treatment of choice for intermediate-stage hepatocellular carcinoma (HCC). Recent data suggest that TACE may boost the efficacy of anti-PD-1 immunotherapy. The authors present the trial protocol for PETAL, a phase Ib study, which will assess the safety and bioactivity of pembrolizumab, an anti-PD-1 antibody, following TACE in HCC. After a run-in phase evaluating six patients to establish preliminary safety, up to 26 additional participants will be enrolled. Pembrolizumab will be administered three-Times weekly for 1 year or until progression, starting 30-45 days after TACE. The primary objective is to determine safety and the secondary objective is to preliminarily evaluate efficacy. Radiological responses will be evaluated every four cycles. Clinical Trial Registration: NCT03397654 (ClinicalTrials.gov.
Original language | English |
---|---|
Pages (from-to) | 499-507 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 19 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Mar 2023 |
Keywords
- PD-1
- hepatocellular carcinoma
- immune checkpoint inhibitor
- immunotherapy
- pembrolizumab
- transarterial chemoembolization